Latest Breaking News On - National reimbursement drug list - Page 8 : vimarsana.com

China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®

China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
China
Shenzhen
Guangdong
Macao
Macau-general
Macau
Taiwan
Chinese
Meixiang-chen
Urol-nephrol
Clin-nephrol

Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health Sciences Authority

Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health Sciences Authority
wahanariau.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wahanariau.com Daily Mail and Mail on Sunday newspapers.

Canada
San-francisco
California
United-states
Suzhou
Jiangsu
China
Beijing
United-kingdom
Guangzhou
Guangdong
Australia

China Medical System (00867） Obtained Exclusive License of

SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February.

China
Macao
Macau-general
Macau
Shenzhen
Guangdong
Taiwan
Chinese
Urol-nephrol
Clin-nephrol
Meixiang-chen
Kidney-international-supplements

China Medical System (00867） Obtained Exclusive License Of A First-Line Phosphate-Lowering Drug Velphoro®

China Medical System (00867） Obtained Exclusive License Of A First-Line Phosphate-Lowering Drug Velphoro®
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

China
Taiwan
Macao
Macau-general
Macau
Shenzhen
Guangdong
Chinese
Clin-nephrol
Chinj-nephrol
Meixiang-chen
Urol-nephrol

Exclusive-Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth

Japan’s Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, a company spokesperson told Reuters. More convenient Alzheimer's blood tests expected to be ready then could help Eisai reach a bigger share of China’s estimated 17 million people with early-stage disease, the spokesperson said. “China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer’s disease for Eisai,” a company spokesperson said.

South-korea
Shanghai
China
Japan
Liu-zhou
Guangxi
Guangdong
Jilin
Chicago
Illinois
United-states
Taiwan